The Administration unit of the Sidney Kimmel Cancer Center (SKCC) provides comprehensive programmatic direction and administrative support to all aspects of the Center. Under the direction of Dr. Knudsen and the re-aligned leadership structure, an entirely new Administration mission and focus was implemented, aligned with the strategic plan (IMPACT). Administration strives to complete this mission by providing comprehensive oversight in the follow seven areas: 1) Facilitating the strategic planning processes and continued implementation of IMPACT; 2) Prioritizing catchment-related issues pertaining to programmatic development and community outreach; 3) Documentation, organization, and communication related to SKCC-organized activities; 4) Oversight of the CCSG application, fiscal management of funds, adherence to NCI guidelines and CCSG reporting; 5) Operational oversight of space and Shared Resources; 6) Administration of SKCC faculty recruitment and retention efforts; 7) Oversight of pilot fund processes and clinical research operations; 8) Governance of membership processes and consortium relations and/or partner institutions; 9) Facilitates cancer research career enhancement related-initiatives. Through these mechanisms, Administration provides a strong foundational platform to support the Center Director, Senior Leaders, Programs, Shared Resources, TIPS mechanism, and key leadership committees. Furthermore, Administration is integrated into the SKCC Executive Committee, which is now the governing body of the Center. This committee meets weekly and includes major responsibilities outlining: strategy, resource deployment, policy, strategic alliances, high-level management of SKCC clinical operations, research, education, assessment of catchment area needs, and outreach activities. SKCC Administration is comprised of a well-trained, comprehensive staff that are aligned to support the 159 members of SKCC as well as Senior Leaders, the Clinical Research Organization, and Shared Resource operations. Although SKCC Administration is comprised of more than 15 members in various diverse roles, support for only 2 FTE equivalents is requested during this CCSG project period. In the next funding cycle Administration endeavors to: 1) Refine mechanisms to support the expanding SKCC research mission including basic, clinical and population science related to catchment area needs; 2) Enhance communication efforts that promote the goals of the strategic plan, awareness and outreach through the facilitation of transdisciplinary research; 3) Tighten administrative efficiencies to reduce the burden on investigators and develop new capabilities for administrative oversight.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA056036-19
Application #
9492084
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
19
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603
Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38:
Waldman, Scott A; Camilleri, Michael (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 67:1543-1552
Sullivan-Reed, Katherine; Bolton-Gillespie, Elisabeth; Dasgupta, Yashodhara et al. (2018) Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep 23:3127-3136
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35

Showing the most recent 10 out of 807 publications